SCHEDULE: ExodusPoint Capital Management Discloses Spruce Biosciences Stake

ExodusPoint Capital Management, LP, along with affiliated entities, has reported beneficial ownership of 0.8% of Spruce Biosciences, Inc. common stock as of April 27, 2026.

Summary

• ExodusPoint Capital Management, LP, ExodusPoint Capital Partners GP, LLC, and Michael Gelband have jointly filed a Schedule 13G.
• They collectively beneficially own 22,000 shares of Spruce Biosciences, Inc. common stock.
• This ownership represents approximately 0.8% of the class of securities outstanding as of April 27, 2026.
• The shares are held directly by ExodusPoint Partners Master Fund, LP.
• ExodusPoint Capital Management has investment and voting power over the shares held by the Master Fund.
• ExodusPoint Capital Partners GP, LLC is the general partner of ExodusPoint Capital Management.
• Michael Gelband controls both ExodusPoint Capital Management and ExodusPoint Capital Partners.
• The filing indicates that none of the reporting persons directly own shares, and they share voting and dispositive power over the 22,000 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership without any indication of company performance or strategic changes.

Positives

• The filing clearly outlines the beneficial ownership structure and the percentage of shares held, providing transparency to the market.
• The joint filing agreement ensures coordinated reporting and compliance.

Negatives

• The filing does not contain any financial performance data or operational updates for Spruce Biosciences, Inc., limiting insight into the company's health.

Risks

• The filing does not explicitly mention any risks associated with Spruce Biosciences, Inc. or the reporting persons' investment.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Spruce Biosciences, Inc.'s future performance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard disclosures for institutional investors acquiring a significant stake in a public company, indicating a passive investment approach unless otherwise specified. This filing provides insight into the holdings of ExodusPoint Capital Management within the biotechnology sector.

Stakeholder Impact

• Shareholders of Spruce Biosciences, Inc. are informed of a significant institutional investor's stake, which may influence market perception.
• The filing provides transparency regarding the ownership structure, which is a standard practice for regulatory compliance.

Next Steps

• ExodusPoint Capital Management, LP, ExodusPoint Capital Partners GP, LLC, and Michael Gelband will file amendments to this statement if any material changes occur in their beneficial ownership.

Key Dates

Keywords

Schedule 13G, Spruce Biosciences, ExodusPoint Capital Management, Beneficial Ownership, SEC Filing, Investment Management, Securities